Virtual Investor is a leading platform providing investors with direct access to innovative companies, management teams and thought leaders.
Covered Companies
Covered Companies
Series
CEO Connect
Featuring SENTI Bio
January 14, 2026
Timothy Lu, MD, PhD, CEO of Senti, discusses its recent news release announcing that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to SENTI-202, the Company’s potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer (CAR-NK) investigational cell therapy, that is currently in development for the treatment of relapsed/refractory hematologic malignancies, including AML.
What This Means
Featuring Autonomix
December 23, 2025
Brad Hauser, CEO of Autonomix, outlines two key priorities shaping the Company’s trajectory: strengthening its platform through intellectual property protection and evaluating opportunities beyond pancreatic cancer, including potential applications in cardiovascular, pulmonary and interventional pain management areas.
What This Means
Featuring Akari Therapeutics
December 18, 2025
Abizer Gaslightwala, President and CEO of Akari Therapeutics highlights the recently announced new preclinical data that demonstrates the therapeutic potential of Akari’s lead ADC AKTX-101 in hard-to-treat KRAS-mutant pancreatic cancer.
What This Means
Featuring American Resources
December 8, 2025
Mark Jensen, Executive Chairman of American Resources and CEO of ReElement Technologies, and Jacob Clayton, CEO of SAGINT Inc., discuss the strategic collaboration between the companies to implement blockchain-based tokenization for global critical mineral traceability and transparency.
What This Means
Featuring Ernexa Therapeutics
November 6, 2025
Sanjeev Luther, President and CEO of Ernexa, discusses the Company’s recently announced partnership agreement with Cellipont Bioservices focused on Engineering, Differentiation, and Production (EDP) activities to advance ERNA-101, Ernexa’s lead cell therapy for the treatment of ovarian cancer, into clinical manufacturing and clinical trials.
What This Means
Featuring HCW Biologics
October 22, 2025
Dr. Peter Rhode, PhD, Chief Scientific Officer and Vice President of Clinical Operations of HCW Biologics, discusses the Company’s lead product candidate, known as HCW11-040, which is the Company’s franchise immunotherapeutic for internal clinical development as a second-generation immune checkpoint inhibitor.
What This Means
Featuring HCW Biologics
September 30, 2025
Dr. Peter Rhode, PhD, Chief Scientific Officer and Vice President of Clinical Operations of HCW Biologics discusses the Company’s recent news announcing its second-generation T-Cell Engager program. The Company has joined a small group of innovative biotechnology companies who have discovered new compounds that overcome resistance mechanisms and improve the ability to treat solid tumors.
Past Events
Closing Bell
CEO Connect